Description

Zepbound 15mg

On November 8, 2023, Eli Lilly and Company’s obesity treatment Zepbound™ was approved by the U.S. Food and Drug Administration (FDA). It is projected to work better compared to other weight loss drugs on the market  Zepbound 15mg.

Zepbound has a unique mechanism of action that sets it apart from other weight-loss medications. It activates two hormone receptors in the body called GIP and GLP-1 receptors. GLP-1 is a hormone that helps regulate appetite and food intake. Based on preliminary lab studies, GIP is another hormone that may further reduce food cravings and calorie consumption when combined with GLP-1. It is designed to supplement diet and exercise and helps with chronic weight management.
Inactive ingredients include sodium chloride and sodium phosphate dibasic heptahydrate. Sodium hydroxide solution or hydrochloric acid solution may have been used to adjust pH. Water for injection is also added.
It is used to treat certain conditions, specifically for adults with obesity (meaning severely overweight) or who are overweight, and for those who have at least one of the following weight-related medical problems:

hypertension (high blood pressure),

type 2 diabetes (a long-term condition where your body has trouble using sugar for energy, leading to high blood sugar levels),

sleep apnea (a sleep disorder characterized by pauses in breathing during sleep), dyslipidemia (an imbalance in fats in your blood), or

cardiovascular diseases (conditions affecting the heart and blood vessels).

Buy Zepbound 15mg Online

Zepbound (Tizepatide) is still awaiting registration with the Therapeutic Goods Administration (TGA), USA’s medicine safety and governing body. Zepbound contains the same active ingredients as Mounjaro (Tizepatide) but for a different therapeutic use and has been cleared by the USA’s Food and Drug Administration (FDA) as well as the UK’s medicines regulator in late 2023.
Before release in USA Zepbound manufacturer Eli Lilly will need to gain approval from the TGA and secure enough stock to adequately and consistently meet demand in the USA market. This is particularly important as Zepbound, like other GLP-1 receptor agonist treatments, is likely to experience high demand and have complex storage, transport and manufacturing challenges to keep up with it. Mounjaro is just like Zepbound